Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 12, 2010, Pages 2215-2221

  Lourenço, Gustavo J ^a   Lorand Metze, Irene ^a   Delamain, Marcia T ^a   Miranda, Eliana C M ^a   Kameo, Rodolfo ^a   Metze, Konradin ^a   Lima, Carmen S P ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

GSTM1; GSTP1; GSTT1; Hodgkin lymphoma; prognosis

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELLULITIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENOTYPE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INFECTION; LIVER TOXICITY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUTROPENIA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 78650037212     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.527402     Document Type: Article

References (36)

1. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkins disease. N Engl J Med 2003;348:2386-2395.
2. Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P. Survival in Hodgkins disease patients - report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005;41:998-1006.
3. OBrien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996;32A:967-978.
4. OBrien M, Kruh GD, Tew KD. The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther 2000; 294:480-487.
5. Goto S, Ihara Y, Urata Y, et al. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase P1. FASEB J 2001;15:2702-2714.
6. Townsend DM, Tew KD. The role of glutathione-Stransferase in anti-cancer drug resistance. Oncogene 2003;22: 7369-7375.
7. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88.
8. Lo HW, Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 2007;7:367-374.
9. Kellen E, Hemelt M, Broberg K, et al. Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. Am J Epidemiol 2007;165:1221-1230.
10. Zimniak P, Nanduri B, Pikula S, et al. Naturally occurring human glutathione S-transferase GSTP1 isoforms with isoleucine and valine in position 104 differ in enzymatic properties. Eur J Biochem 1994;224:893-899.
11. Sundberg K, Johansson AS, Stenberg G, et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase PI-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998;19:433-436. (Pubitemid 28375445)
12. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Plácido F, Regateiro FJ. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999;20:1225-1229.
13. Sarmanová J, Benesová K, Gut I, Nedelcheva-Kristensen V, Tynková L, Soucek P. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkins and non- Hodgkins lymphomas. Hum Mol Genet 2001;10:1265-1273.
14. Soucek P, Sarmanová J, Kristensen VN, Apltauerová M, Gut I. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkins and non-Hodgkins lymphomas. Int Arch Occup Environ Health 2002;75:S86-S92.
15. Hohaus S, Massini G, DAlo F, et al. Association between glutathione S-transferase genotypes and Hodgkins lymphoma risk and prognosis. Clin Cancer Res 2003;9:3435-3440.
16. Hohaus S, Di Ruscio A, Di Febo A, et al. Glutathione Stransferase P1 genotype and prognosis in Hodgkins lymphoma. Clin Cancer Res 2005;11:175-2179.
17. Ribrag V, Koscielny S, Casasnovas O, et al. Pharmacogenetic study in Hodgkins lymphomas reveals the impact of UGT1A1 polymorphisms on patients prognosis. Blood 2009;113:3307-3313.
18. Duncan BB, Schmidt MI, Polansky CA. High mortality rates among Brazilian adult populations-an international comparison. Rev Assoc Med Bras 1992;38:138-144.
19. Souza CA, Vassallo J, Lorand-Metze I. Hodgkins disease in Brazil: a clinical-pathological study. Haematologica 1997;82: 127-128.
20. Lourenço GJ, Neri IA, Sforni VCS, Kameo R, Lorand-Metze I, Lima CSP. Polymorphisms of glutathione S-transferase Mu 1, glutathione S-transferase theta 1 and glutathione Stransferase Pi 1 genes in Hodgkins lymphoma susceptibility and progression. Leuk Lymphoma 2009;50:1005-1009.
21. Stein H. Hodgkin lymphoma. In: Swerdlow S, Camp E, Harris N, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp.
22. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee of Hodgkins Disease Staging Classification. Cancer Res 1971;31:1860-1861.
23. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkins disease. N Engl J Med 1998;339:1506-1514.
24. Comstock KE, Sanderson BJS, Clafin G, Hener WD. GST1 gene deletion determined by polymerase chain reaction. Nucleic Acids Res 1990;18:3670-3676.
25. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-276.
26. Irazusta SP, Vassallo J, Magna LA, Metze K, Trevisan M. The value of PCNA and AgNOR staining in endoscopic biopsies of gastric mucosa. Pathol Res Pract 1998;194:33-39.
27. Cia EM, Trevisan M, Metze K. Argyrophilic nucleolar organizer region (AgNOR) technique: a helpful tool for differential diagnosis in urinary cytology. Cytopathology 1999;10:30-39.
28. Lorand-Metze I, Pinheiro MP, Ribeiro E, de Paula EV, Metze K. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 2004;28:587-594.
29. Bedin V, Adam RL, Sá BCS, Landman G, Metze K. Fractal dimension is an independent prognostic factor for survival in melanoma. BMC Cancer 2010;10:260.
30. Lorand-Metze I, Pinheiro MP, Ribeiro E, de Paula EV, Metze K. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 2004;28:587-594.
31. Engert A. Aktuelle Therapiestrategien der Deutschen Hodgkin Studiengruppe. Onkologe 2010;16:28-34.
32. Han X, Zheng T, Foss FM, et al. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol 2010;85:51-56.
33. Dieckvoss BO, Stanulla M, Schrappe M, et al. Polymorphisms within glutathione S-transferase genes in pediatric non- Hodgkins lymphoma. Haematologica 2002;87:709-713.
34. Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics 2010;11:607-611.
35. Gilliland FD, Li Y-F, Saxon A, Diaz-Sanchez D. Effect of glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: randomized, placebocontrolled crossover study. Lancet 2004;363:119-125.
36. Kü ppers R. B cells under influence: transformation of Bcells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-812.